XML 93 R69.htm IDEA: XBRL DOCUMENT
v3.22.4

ACQUISITIONS AND OTHER ARRANGEMENTS (Details) - USD ($) | 1 Months Ended | 3 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | ---
Sep. 30, 2022 | Aug. 31, 2022 | Jun. 30, 2022 | May 31, 2022 | Dec. 31, 2021 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | Apr. 30, 2021 | Jul. 03, 2015
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Payment for acquisition options |  |  |  |  |  | $ 109,600,000 | $ 13,100,000 | $ 10,000,000.0 |  |
Carrying value of non-marketable equity securities |  |  |  |  | $ 84,100,000 | 86,900,000 | 84,100,000 |  |  |
Kardion, Inc. |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Carrying value of non-marketable equity securities |  |  |  |  |  |  |  |  | $ 35,900,000 |
Investment option to acquire |  |  |  |  |  |  |  |  | 5,700,000 |
Maximum additional option to acquire investment |  |  |  |  |  |  |  |  | 21,800,000 |
Investment after first milestone |  |  |  |  | $ 10,800,000 |  |  |  |  |
Maximum secured promissory note |  |  |  |  |  |  |  |  | 45,000,000 |
Secured promissory note |  |  |  |  |  | 0 |  |  |  |
Kardion, Inc. | Equity Securities |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Maximum additional required investment |  |  |  |  |  |  |  |  | $ 9,900,000 |
Variable Interest Entity, Not Primary Beneficiary | Medical Device Company |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Payment for acquisition options |  | $ 47,100,000 | $ 35,000,000 |  |  |  |  |  |  |
Option to acquire investment amount |  | $ 47,100,000 |  |  |  | 35,000,000 |  |  |  |
Loans receivables, maximum lending amount |  |  | $ 47,500,000 |  |  |  |  |  |  |
Financing receivable |  |  |  |  |  | 32,500,000 |  |  |  |
Variable Interest Entity, Not Primary Beneficiary | Medical Technology Company |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Payment for acquisition options |  |  |  | $ 60,000,000 |  |  | 10,000,000 |  |  |
Option to acquire investment amount |  |  |  | $ 60,000,000 |  |  |  |  |  |
In-process Research and Development |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Impairment charges |  |  |  |  |  | $ 52,700,000 | $ 0 | $ 0 |  |
Harpoon Medical | In-process Research and Development |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Impairment charges | $ 28,100,000 |  |  |  |  |  |  |  |  |
CardiAQ |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |
Additional research and development expenditures to be incurred prior to product introduction |  |  |  |  |  |  |  |  |  | $ 97,700,000

X
- Definition Business Combination, In-process Research and Development, Expected Costs + References No definition available. + Details
Name: | ew_BusinessCombinationInprocessResearchandDevelopmentExpectedCosts
Namespace Prefix: | ew_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Equity Securities, FV-NI, Investment After First Milestone + References No definition available. + Details
Name: | ew_EquitySecuritiesFVNIInvestmentAfterFirstMilestone
Namespace Prefix: | ew_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Equity Securities, FV-NI, Maximum Additional Option To Acquire Investment + References No definition available. + Details
Name: | ew_EquitySecuritiesFVNIMaximumAdditionalOptionToAcquireInvestment
Namespace Prefix: | ew_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Equity Securities, FV-NI, Maximum Additional Required + References No definition available. + Details
Name: | ew_EquitySecuritiesFVNIMaximumAdditionalRequired
Namespace Prefix: | ew_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Equity Securities, FV-NI, Maximum Secured Promissory Note + References No definition available. + Details
Name: | ew_EquitySecuritiesFVNIMaximumSecuredPromissoryNote
Namespace Prefix: | ew_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Equity Securities, FV-NI, Option To Acquire Investment + References No definition available. + Details
Name: | ew_EquitySecuritiesFVNIOptionToAcquireInvestment
Namespace Prefix: | ew_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Equity Securities, FV-NI, Promissory Note + References No definition available. + Details
Name: | ew_EquitySecuritiesFVNIPromissoryNote
Namespace Prefix: | ew_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Loans Receivables, Maximum Lending Capacity + References No definition available. + Details
Name: | ew_LoansReceivablesMaximumLendingCapacity
Namespace Prefix: | ew_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Option To Acquire Investment, Amount + References No definition available. + Details
Name: | ew_OptionToAcquireInvestmentAmount
Namespace Prefix: | ew_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 45 -Paragraph 1A -URI https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740 + Details
Name: | us-gaap_EquitySecuritiesFvNi
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585 + Details
Name: | us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amortized cost, before allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section 50 -Paragraph 7A -URI https://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 326 -SubTopic 20 -Section 55 -Paragraph 79 -URI https://asc.fasb.org/extlink&oid=124267575&loc=SL82922352-210448 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(b)) -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 326 -SubTopic 20 -Section 50 -Paragraph 14 -URI https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447 Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 326 -SubTopic 20 -Section 45 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 326 -SubTopic 20 -Section 50 -Paragraph 5 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 326 -SubTopic 20 -Section 55 -Paragraph 80 -URI https://asc.fasb.org/extlink&oid=124267575&loc=SL82922355-210448 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher SEC -Name Regulation S-K (SK) -Number 229 -Section 1405 -Paragraph (a) -Subparagraph (1) Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher SEC -Name Regulation S-K (SK) -Number 229 -Section 1405 -Paragraph (a) -Subparagraph (2) Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher SEC -Name Regulation S-K (SK) -Number 229 -Section 1404 -Paragraph (a) + Details
Name: | us-gaap_NotesReceivableGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585 + Details
Name: | us-gaap_OtherPaymentsToAcquireBusinesses
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ew_KardionIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ew_MedicalDeviceCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ew_MedicalTechnologyCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=ew_HarpoonMedicalInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=ew_CardiAQValveTechnologiesInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |